Renal and electrolyte disturbances associated with cisplatin

Area of Science:

• Nephrology
• Oncology
• Medicinal Chemistry

Background:

• Cisplatin is a platinum-based chemotherapy agent with significant antineoplastic effects.
• Nephrotoxicity is a major dose-limiting toxicity, occurring in 50-75% of patients, primarily due to renal tubular injury.
• Cisplatin also causes renal magnesium wasting, impacting electrolyte balance.

Purpose of the Study:

• To review strategies for mitigating cisplatin-induced nephrotoxicity.
• To explore methods for preventing renal tubular injury associated with cisplatin treatment.
• To address the issue of cisplatin-associated renal magnesium wasting.

Main Methods:

• Review of available clinical data and preliminary animal studies.
• Analysis of factors influencing cisplatin nephrotoxicity.
• Assessment of potential preventive measures.

Main Results:

• Slow infusion rates, pre- and post-hydration, and mannitol administration may reduce cisplatin nephrotoxicity.
• Chloride-containing vehicles, such as 0.9% sodium chloride, may decrease cisplatin toxicity by preventing aquation/hydroxylation.
• No specific preventive strategies for cisplatin-associated renal magnesium wasting are established, but monitoring and replacement of serum cations are recommended.

Conclusions:

• Cisplatin nephrotoxicity can be potentially reduced through specific administration protocols and supportive care.
• Further research is needed to establish definitive prevention strategies for cisplatin-induced renal magnesium wasting.
• Close monitoring of renal function and electrolyte levels is crucial for patients receiving cisplatin therapy.